Bulk Pharmaceutical API Sources for nonoxynol-9

Bulk Pharmaceutical API Sources for nonoxynol-9

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		72385
ABI Chem		AC1L2HZ4
ABI Chem		AC1Q56ZY
ISpharm		I14-40150

Nonoxynol-9 Bulk API Manufacturing Landscape

Last updated: February 19, 2026

Nonoxynol-9, an active pharmaceutical ingredient (API) primarily used as a spermicide and as a nonionic surfactant, faces a manufacturing landscape characterized by established, albeit evolving, production methodologies and a limited number of key global suppliers. The synthesis of nonoxynol-9 involves the ethoxylation of nonylphenol. The precise chain length of the polyethylene glycol moiety is critical for its efficacy and safety profile.

What Are the Primary Manufacturing Processes for Nonoxynol-9 API?

The core manufacturing process for nonoxynol-9 API is the ethoxylation of nonylphenol. This reaction involves reacting nonylphenol with ethylene oxide. The degree of ethoxylation, i.e., the average number of ethylene oxide units added, determines the specific properties of the nonoxynol-9 product. Typically, nonoxynol-9 refers to a mixture of ethoxylates with an average of nine ethylene oxide units.

The general reaction is as follows:

Nonylphenol + n Ethylene Oxide → Nonylphenol Ethoxylate (where n is the average degree of ethoxylation)

Key parameters in this process include:

• Catalyst: Alkaline catalysts, such as sodium hydroxide (NaOH) or potassium hydroxide (KOH), are commonly used to initiate and facilitate the ethoxylation reaction.
• Temperature and Pressure: The reaction is typically conducted under controlled temperature (e.g., 100-200°C) and pressure (e.g., 1-10 bar) to manage the reactivity of ethylene oxide and optimize product yield and consistency.
• Raw Material Purity: The purity of both nonylphenol and ethylene oxide is crucial. Impurities in nonylphenol, such as other phenolic compounds, can lead to byproducts. Residual ethylene oxide must be minimized in the final API.
• Post-Reaction Processing: After ethoxylation, neutralization of the catalyst is performed, followed by purification steps, which may include filtration, distillation, or drying, to achieve the required API specifications.

Who Are the Dominant Manufacturers and Suppliers of Nonoxynol-9 Bulk API?

The global supply of nonoxynol-9 bulk API is concentrated among a few key manufacturers. These companies possess the specialized equipment and expertise required for ethoxylation reactions and adherence to stringent pharmaceutical quality standards.

Key Manufacturers and Their Geographic Presence:

• Clariant AG (Switzerland): A significant global player in specialty chemicals, Clariant produces nonoxynol-9 as part of its broad portfolio of surfactants. Their production facilities are strategically located to serve major pharmaceutical markets.
• BASF SE (Germany): As one of the world's largest chemical producers, BASF is involved in the synthesis of various ethoxylated compounds, including nonoxynol-9. Their extensive production network and commitment to quality make them a reliable supplier.
• Dow Inc. (USA): Dow is another major chemical company with capabilities in ethoxylation chemistry. They supply nonoxynol-9 for various applications, including pharmaceutical uses, through their global manufacturing and distribution channels.
• Sarex Technologies Pvt. Ltd. (India): Sarex is a prominent Indian manufacturer of specialty chemicals, including nonoxynol-9. Indian manufacturers have become increasingly important in the global API supply chain due to cost efficiencies and expanding manufacturing capacity.
• Other Asian Manufacturers: Several other chemical manufacturers in China and South Korea also produce nonoxynol-9, though their scale and market penetration for pharmaceutical-grade API may vary. These suppliers often cater to a broader industrial chemical market as well.

Note: The specific branding and product names for nonoxynol-9 may differ across manufacturers. Pharmaceutical companies often source nonoxynol-9 under specific quality agreements and batch testing protocols.

What Are the Regulatory Requirements and Quality Standards for Nonoxynol-9 API?

Compliance with rigorous regulatory standards is mandatory for nonoxynol-9 intended for pharmaceutical use. These standards ensure the safety, efficacy, and purity of the API.

Key Regulatory Aspects:

• Pharmacopoeial Standards: Nonoxynol-9 API must meet the specifications outlined in major pharmacopoeias, including:
  • United States Pharmacopeia (USP): The USP monograph for Nonoxynol 9 defines tests for identification, assay (typically for total ethoxylates and a specific average ethoxy number), impurities (e.g., free phenol, residual ethylene oxide), and physical properties.
  • European Pharmacopoeia (Ph. Eur.): Similar to USP, the Ph. Eur. monograph sets forth standards for purity and quality.
  • Japanese Pharmacopoeia (JP): JP also has specific requirements for nonoxynol-9.
• Good Manufacturing Practices (GMP): API manufacturers must adhere to current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This includes:
  • Quality Management Systems: Robust systems for process control, documentation, and batch release.
  • Facility and Equipment: Validation and maintenance of manufacturing facilities and equipment.
  • Personnel Training: Qualified and trained personnel.
  • Raw Material Control: Strict testing and qualification of incoming raw materials.
  • Process Validation: Demonstrating that the manufacturing process consistently produces API meeting predetermined specifications.
• Impurity Profiling: Detailed analysis and control of impurities are critical. This includes:
  • Residual Solvents: If solvents are used in the purification process.
  • Heavy Metals: Limits for specific heavy metal contaminants.
  • Related Substances: Byproducts of the ethoxylation reaction, such as lower or higher ethoxylates, or unreacted nonylphenol.
  • Ethylene Oxide and 1,4-Dioxane: Strict limits are imposed due to their potential toxicity. 1,4-Dioxane is a common byproduct of ethoxylation.
• Drug Master Files (DMFs): API manufacturers often submit Drug Master Files to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality controls, which can be referenced by drug product manufacturers in their regulatory submissions.

What Are the Current Market Trends and Challenges in Nonoxynol-9 API Supply?

The market for nonoxynol-9 API is influenced by several trends and faces specific challenges.

Key Market Trends:

• Sustained Demand for Spermicides: Despite the availability of other contraceptive methods, nonoxynol-9-based spermicides maintain a market share, particularly in specific regions or demographic groups. This sustains a baseline demand for the API.
• Evolving Regulatory Scrutiny: Increased focus on impurity profiles, particularly for genotoxic impurities like 1,4-dioxane, necessitates continuous process improvement and advanced analytical capabilities from manufacturers.
• Geographic Shift in Manufacturing: A growing proportion of bulk API manufacturing, including nonoxynol-9, has shifted to Asia (India and China) due to cost advantages and expanding chemical synthesis infrastructure.
• Consolidation Among Suppliers: The specialty chemical and API manufacturing sectors are prone to consolidation, which can impact pricing and supply chain resilience.
• Competition from Alternative APIs: While nonoxynol-9 is established, the development of novel contraceptive technologies or spermicidal agents could, over the long term, affect its market position.

Key Challenges:

• Supply Chain Vulnerabilities: Dependence on a limited number of key suppliers, coupled with potential geopolitical instability or trade disputes, can create supply chain risks.
• Cost Pressures: Pharmaceutical companies continually seek cost-effective API sourcing, putting pressure on manufacturers to optimize production efficiencies while maintaining quality.
• Environmental and Safety Concerns: The manufacturing process involves hazardous materials like ethylene oxide. Strict adherence to environmental regulations and worker safety protocols adds to operational costs.
• Impurity Control Complexity: Achieving and consistently demonstrating compliance with stringent limits for specific impurities, such as 1,4-dioxane, requires sophisticated analytical techniques and process control.
• Raw Material Price Volatility: Fluctuations in the prices of nonylphenol and ethylene oxide, which are derived from petrochemical feedstocks, can impact the cost of nonoxynol-9.

What Are the Typical Specifications for Pharmaceutical-Grade Nonoxynol-9 API?

Pharmaceutical-grade nonoxynol-9 API is characterized by specific quality attributes defined by pharmacopoeial monographs and customer requirements.

Typical Specification Parameters:

Parameter	Specification	Test Method (Example)
Appearance	Clear, colorless to pale yellow, viscous liquid.	Visual
Identification	Infrared spectrum corresponds to the reference standard.	USP <197>
Assay (Average Ethoxy Number)	Typically between 8.5 and 9.5 (for Nonoxynol 9). The average number of ethylene oxide units per molecule. This is determined by specific analytical methods that quantify the ethoxy chain length distribution.	Titration/Chromatography
Assay (Total Ethoxylates)	Typically not less than 90% (or as per specific monograph).	USP/Ph. Eur.
Free Phenol (Nonylphenol)	Not more than 0.5% (or as per specific monograph). Limits are strict to minimize potential irritant effects.	USP/Ph. Eur.
Ethylene Oxide (Residual)	Not more than 1 ppm (or as per specific monograph). Due to toxicity.	GC
1,4-Dioxane	Not more than 10 ppm (often significantly lower, e.g., <1 ppm for specific applications or as per customer agreement). A critical genotoxic impurity.	GC-MS
Heavy Metals	Not more than 10 ppm (or as per specific monograph).	USP <231>
Water Content	Not more than 1.0% (or as per specific monograph).	Karl Fischer Titration
pH (of a solution)	Typically between 5.0 and 8.0 (for a defined concentration in water).	pH Meter

Note: Specific limits may vary slightly between pharmacopoeias (USP, Ph. Eur., JP) and are subject to revision. Customers may also impose tighter in-house specifications.

How Does Nonoxynol-9 API Compare to Other Spermicidal APIs in Terms of Efficacy and Safety?

Nonoxynol-9 is one of the most widely used spermicidal APIs. Its efficacy and safety profile are well-established but also subject to ongoing evaluation.

Comparison Points:

• Efficacy: Nonoxynol-9 functions by disrupting the sperm cell membrane, increasing its permeability and rendering the sperm immobile and unable to fertilize an egg. Its effectiveness as a contraceptive is dose-dependent and influenced by proper application. While effective, it is generally considered less effective than hormonal contraceptives or barrier methods when used alone.
• Safety Profile:
  • Irritation: The primary safety concern associated with nonoxynol-9 is its potential to cause irritation to vaginal and cervical tissues. This risk increases with more frequent use or higher concentrations.
  • Increased HIV Transmission Risk: Some studies have suggested a correlation between frequent nonoxynol-9 use and an increased risk of HIV transmission. This has led to recommendations to avoid its use as a primary HIV prevention method and has impacted its market perception in some regions.
  • Allergic Reactions: While uncommon, allergic reactions can occur.
• Comparison with Other APIs:
  • Octoxynol-9: Another nonionic surfactant used as a spermicide. It shares a similar mechanism of action and potential for irritation as nonoxynol-9.
  • Benzalkonium Chloride: A cationic surfactant that acts as a spermicide and antiseptic. It has a different mechanism of action and can also cause irritation.
  • Menfegol: An older spermicide, less commonly used now due to efficacy and safety concerns.
  • Other Contraceptive Methods: Hormonal contraceptives (e.g., birth control pills, implants, injections), IUDs, and barrier methods (e.g., condoms, diaphragms) offer different efficacy and safety profiles. These are often considered more reliable for pregnancy prevention and may have fewer direct tissue irritation risks compared to spermicides.

The regulatory landscape and scientific understanding of nonoxynol-9's long-term effects continue to evolve, influencing its recommendation and use in healthcare guidelines.

Key Takeaways

The manufacturing of nonoxynol-9 bulk API is a mature process dominated by established chemical companies utilizing ethoxylation technology. Key suppliers are located in Europe and Asia, with a growing contribution from Indian manufacturers. Regulatory compliance, particularly adherence to pharmacopoeial standards and GMP, is paramount. The API's primary challenges include supply chain resilience, cost pressures, and stringent impurity control, especially for 1,4-dioxane. While demand for nonoxynol-9 persists due to its established use in spermicides, ongoing safety evaluations, particularly regarding irritation and potential links to increased HIV transmission, shape its market position relative to other contraceptive methods.

FAQs

1. What is the primary function of nonoxynol-9 in pharmaceutical products? Nonoxynol-9 is primarily used as a spermicide in vaginal contraceptives. It also functions as a nonionic surfactant, which can aid in the dispersion and efficacy of other active ingredients in certain formulations.

2. How is the "average ethoxy number" of nonoxynol-9 determined? The average ethoxy number is typically determined through analytical methods that quantify the distribution of ethoxylate chain lengths. Techniques such as gas chromatography (GC) combined with mass spectrometry (GC-MS) or specific titration methods can be employed to measure the average number of ethylene oxide units.

3. What are the main impurities that manufacturers must control in nonoxynol-9 API production? Key impurities requiring strict control include residual nonylphenol (free phenol), residual ethylene oxide, and 1,4-dioxane, which is a byproduct of the ethoxylation process. Heavy metals and other related ethoxylation byproducts also need to be monitored.

4. Are there any significant regulatory changes anticipated that could impact nonoxynol-9 API supply? Regulatory focus often intensifies on impurity profiles, particularly genotoxic impurities like 1,4-dioxane. Manufacturers may face increasing pressure to demonstrate ever-lower levels of these impurities. Additionally, pharmacopoeial monographs are periodically updated, which could introduce new or revised testing requirements.

5. What is the typical shelf life for pharmaceutical-grade nonoxynol-9 API? The shelf life of nonoxynol-9 API is generally dependent on its packaging, storage conditions (temperature, light exposure), and the manufacturer's specific stability data. However, when stored under recommended conditions, it typically has a shelf life of 2 to 3 years. Manufacturers provide specific expiry dates and storage recommendations.

Citations

[1] United States Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary (USP-NF). U.S. Pharmacopeia.

[2] European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia (Ph. Eur.). EDQM.

[3] Japanese Pharmacopoeia. (2023). The Japanese Pharmacopoeia. Pharmaceutical and Medical Devices Agency.

[4] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from FDA website.

[5] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from EMA website.

[6] Clariant AG. (n.d.). Product Portfolio. Retrieved from Clariant website.

[7] BASF SE. (n.d.). Product Portfolio. Retrieved from BASF website.

[8] Dow Inc. (n.d.). Product Portfolio. Retrieved from Dow website.

[9] Sarex Technologies Pvt. Ltd. (n.d.). Product Portfolio. Retrieved from Sarex website.